Dandekar Atul sold $169K of MAZE
Dandekar Atul (CSBO) sold 6,434 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.81–$27.12, $0.17M total) across 4 trades over 2026-09-02 to 2026-09-03.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which may be interpreted by traders as a bearish cue, though the amount is modest.
Market read
A small insider sale; likely limited price impact unless accompanied by other news.
What to watch
No 10b5-1 plan; the insider may be diversifying holdings.
Background
Form 4 filings disclose insider transactions and are primary sources for insider activity.
Ticker impact
Officer Dandekar Atul sold 6,434 shares for $168,811, reducing his stake to 32,316 shares.
Modest downward pressure over the next few days.
The sale is modest in size relative to market cap and follows a typical 10b5-1 plan, but the insider is a CSBO, making the signal noteworthy.
Market effects
Minimal impact on biotech sector; insider sales are common and rarely move the sector.
No regional effect.
Low global relevance.
Counterpoint
The sale could be routine liquidity need, not a negative signal.
Key entities
- CompanyMaze Therapeutics, Inc.
Biotech company developing therapies for rare diseases.
- OfficerDandekar Atul
Chief Scientific Business Officer of Maze Therapeutics.